Altace Patent Trial Set To Begin Feb. 13
This article was originally published in The Pink Sheet Daily
Executive Summary
King Therapeutics' defense against generic competition of ACE inhibitor Altace (ramipril) is scheduled to go to trial in Boston federal court Feb. 13, CEO Brian Markison said Feb. 7 during the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
You may also be interested in...
Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity
King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.